Mucopolysaccharidosis II, IV-A and VI: First Colombian Neuropsychological Characterization
DOI:
https://doi.org/10.6000/2292-2598.2016.04.01.8Keywords:
Mucopolysaccharidosis, Hunter Syndrome, Morquio A Syndrome, Maroteaux-Lamy Syndrome, Neuropsychological characterization.Abstract
The Mucopolysaccharidosis [MPS] are a group of orphan or rare genetic diseases characterized by lysosomal storage disorders which are recognized by bone malformations and neuropsychological implications that have not been studied so far. For this reason, the first cross-sectional descriptive study of neuropsychological nature was conducted on variants of the disease, Hunter Syndrome [MPS II], Morquio A Syndrome [MPS IV A] and Maroteaux-Lamy syndrome [MPS VI] in 21 children and adolescents aged 3 to 19 years old, at the Colombian Association of Patients with Lysosomal Storage Diseases [ACOPEL, for its Spanish acronym] in Bogotá, Colombia. Results indicate that for the different types of MPS tested is not easy to make a neuropsychological characterization and generalize these results to other populations. However, MPS type II shows moderate to severe cognitive deficit with a compromise in psychomotor development. Morquio A presents average intelligence, and MPS type VI points to deficits partially related to sensory impairment, implying significant differences between them. It is important to continue carrying on this type of studies to achieve a better classification of these diseases according to their cognitive functioning from the neuropsychological perspective.
References
Campos LE, Pérez V, Villavicencio A, González M. Hallazgos oculares en niños con mucopolisacaridosis. Revista Médica del Instituto Mexicano del Seguro Social 2012; 50(5): 523-8.
Hamano K, Hayashi M, Shioda K, Fukatsu R, Mizutani S. Mechanisms of neurodegeneration in Mucopolysaccharidosis II and IIIB: analysis of human brain tissue. Acta Neuropathologica 2008; 115: 547-59. http://dx.doi.org/10.1007/s00401-007-0325-3 DOI: https://doi.org/10.1007/s00401-007-0325-3
Kloska A, Jakóbkiewicz-Banecka J, Narajczyk M, Banecka-Majkutewicz Z, Węgrzyn G. Effects of flavonoids on glycosaminoglycan synthesis: implications for substrate reduction therapy in Sanfilippo disease and other mucopolysaccharidoses. Metabolic Brain Disease 2011; 26: 1-8. http://dx.doi.org/10.1007/s11011-011-9233-2 DOI: https://doi.org/10.1007/s11011-011-9233-2
Maceira MC, Atienza G. Detección precoz de mucopolisacaridosis y oligosacaridosis en el período neonatal mediante cribado poblacional. Revisión sistemática 2006. Madrid, España: Ministerio de Sanidad y Consumo. Avalia-t Nº 2006/08. ISBN: 978-84-95463-46-3
Cimaz R, et al. Joint contractures in the absence of inflammation may indicate Mucopolysaccharidosis. Pediatric Rheumatology 2009; 7(18). http://dx.doi.org/10.1186/1546-0096-7-18 DOI: https://doi.org/10.1186/1546-0096-7-18
Pan D, Sciascia A, Vorhees C, Williams M. Progression of multiple behavioral deficits with various age of onset in a murine model of Hurler Syndrome. Brain Research 2009; 1188: 241-53. http://dx.doi.org/10.1016/j.brainres.2007.10.036 DOI: https://doi.org/10.1016/j.brainres.2007.10.036
Walker R, et al. Anesthesia and airway management in Mucopolysaccharidosis. Journal of Inherited Metabolic Disease 2013; 36: 211-19. http://dx.doi.org/10.1007/s10545-012-9563-1 DOI: https://doi.org/10.1007/s10545-012-9563-1
Wraith J, et al. Mucopolysaccharidosis type II (Hunter syndrome): A clinical review and recommendations for treatment in the era of enzyme replacement therapy. European Journal of Pediatrics 2008; 167: 267-77. http://dx.doi.org/10.1007/s00431-007-0635-4 DOI: https://doi.org/10.1007/s00431-007-0635-4
Shah G, Mahal T, Sharma S. A typical clinical presentation of Mucopolysaccharidosis type II (Hunter syndrome): a case report. Journal of Medical Case Reports 2010; 154(4): 1-4. http://dx.doi.org/10.1186/1752-1947-4-154 DOI: https://doi.org/10.1186/1752-1947-4-154
Algahim M, Almassi GH. Current and emerging management options for patients with Morquio A syndrome. Therapeutics and Clinical Risk Managements 2013; 9: 45-53. http://dx.doi.org/10.2147/TCRM.S24771 DOI: https://doi.org/10.2147/TCRM.S24771
Khedhiri S, Chkioua L, Ferchichi S, Miled A., Laradi S. Polymorphisms in Tunisian patients with N-acetylgalactosamine-6-sulfate sulfatase gene deficiency: Implication in Morquio A disease. Diagnostic Pathology 2011; 6(11): 1-5. http://dx.doi.org/10.1186/1746-1596-6-11 DOI: https://doi.org/10.1186/1746-1596-6-11
Tomatsu, et al. Enhancement of Drug Delivery: Enzyme replacement Therapy for Murine Morquio a Syndrome. The American Society of Gene & Cell Therapy 2010; 18(6): 1094-1102. http://dx.doi.org/10.1038/mt.2010.32 DOI: https://doi.org/10.1038/mt.2010.32
Jurkiewicz E, Marcinska B, Nowacka J, Dobrzanska A. Clinical and radiological pictures of two newborn babies with manifestations of chondrodysplasia punctata and review of available literature. Polish Journal of Radiology 2013; 78(2): 57-64. http://dx.doi.org/10.12659/PJR.883947 DOI: https://doi.org/10.12659/PJR.883947
Kubaski F, et al. Identification of a novel missense mutation in Brazilian patient with a severe form of Mucopolysaccharidosis type IVA. Gene 2013; 517: 112-115. http://dx.doi.org/10.1016/j.gene.2012.12.100 DOI: https://doi.org/10.1016/j.gene.2012.12.100
Tomatsu S, Montaño A, Oikawa H. Mucopolysaccharidosis type IVA (Morquio A disease): clinical review and current treatment: a special review. Current Pharmaceutical Biotechnology 2011; 12(6): 931-945. http://dx.doi.org/10.2174/138920111795542615 DOI: https://doi.org/10.2174/138920111795542615
Brands M, et al. Mucopolysaccharidosis type VI phenotypes-genotypes and antibody response to Galsulfase. Orphanet Journal of Rare Diseases 2013; 8(51). http://dx.doi.org/10.1186/1750-1172-8-51 DOI: https://doi.org/10.1186/1750-1172-8-51
Valayannopoulos V, Nicely H, Harmatz P, Turbeville S. Mucopolysaccharidosis VI. Orphaned Journal of Rare Diseases 2010; 5(5): 1-20. DOI: https://doi.org/10.1186/1750-1172-5-5
Mabe P. Las Mucopolisacaridosis [Versión electrónica], Revista chilena de nutrición 2004; 31(1): 8-16. http://dx.doi.org/10.4067/S0717-75182004000100001 DOI: https://doi.org/10.4067/S0717-75182004000100001
Tessitore A, Pirozzi M, Auricchio A. Abnormal autophagy, ubiquitination, inflammation and apoptosis are dependent upon lysosomal storage and are useful biomarkers of Mucopolysaccharidosis VI. PathoGenetics 2009; 2(4): 1-12. http://dx.doi.org/10.1186/1755-8417-2-4[20] Gagliardi C, Bunnell B. Large Animal Models of Neurological Disorders for Gene Therapy. ILAR Journal 2009; 50(2): 128-143. http://dx.doi.org/10.1093/ilar.50.2.128 DOI: https://doi.org/10.1093/ilar.50.2.128
Scarpa M, et al. Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease. Orphanet Journal of Rare Diseases 2011; 6(72). http://dx.doi.org/10.1186/1750-1172-6-72 DOI: https://doi.org/10.1186/1750-1172-6-72
Federación Colombiana de Enfermedades Raras. Enfermedad rara en Colombia 2012. Available from: http://www.fecoer.org/ enfermedad-rara-en-colombia/
Hernández R, Fernández C, Baptista P.). Metodología de la investigación 2006. México: Mc Graw Hill.
Matute E, Roselli M, Ardila A, Ostrosky-Solís F.). Evaluación Neuropsicológica Infantil (ENI) 2007. Manual Moderno. ISBN 970-729-187-7.
Rosselli M, Matute E, Ardila A, Botero V, Tangarife G, Echeverría S, Arbeláez C. Evaluación Neuropsicológica Infantil (ENI): una batería para la evaluación de niños entre 5 y 16 años de edad. Estudio normativo colombiano. Revista de Neurología 2004; 38(8): 720-731. DOI: https://doi.org/10.33588/rn.3808.2003400
Ramos-Loyo J, Taracena A, Ramos-Loyo L, Matute E, González-Garrido A. Relación entre el funcionamiento ejecutivo en pruebas neuropsicológicas y en el contexto social en niños con TDAH. Revista Neurología, Neuropsiquiatría y Neurociencias 2011; 11(1): 1-16. ISSN: 0124-1265
Strauss E, Sherman E, Spreen O. A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary 2006. Third Edition. New York: Oxford University Press.
Kaufman A, Kaufman N. K-BIT Test Breve de Inteligencia de Kaufman 2009. Adaptación Española (3ª. Ed.). Madrid, España: TEA Ediciones S.A.
Petit G, Kornreich C, Noel X, Verbanck P, Campanella S. Alcohol-Related Context Modulates Performance of Social Drinkers in a Visual Go/No-Go Task: A Preliminary Assessment of Event-Related Potentials. PLoS ONE 2012; 7(5): e37466. http://dx.doi.org/10.1371/journal.pone.0037466 DOI: https://doi.org/10.1371/journal.pone.0037466
Torpey D, Hajcak G, Kim J, Kujawa A, Klein D. Electrocortical and Behavioral Measures of Response Monitoring in Young Children During a Go/No-Go Task. Developmental Psychobiology 2012; 54(2): 139-50. http://dx.doi.org/10.1002/dev.20590 DOI: https://doi.org/10.1002/dev.20590
Vuori-Christiansen L, Ortiz N. Adaptación de la prueba de desarrollo mental de Griffiths a la población de Bogotá. Reordenación de los ítems. Revista Latinoamericana de Psicología 1974; 6(3): 347-61
Colombian Congress. Act 23 of 1982. Which regulate the copyright and intellectual property. Available from: http://www.unesco.org/culture/natlaws/media/pdf/colombia/colombia_ley_23_28_01_1982_spa_orof.pdf
Act 1090-060906 2006. Which regulate the exercise of the profession of psychology; it dictated the Code of Ethics and Bioethics. Chapter 7; Articles 49, 50, 51, 52, 55 and 56, which refer to scientific research, intellectual property and publications.
Act 1392 2010. Through which orphan diseases of special interest are recognized and standards aimed at ensuring social protection by the Colombian State to the people suffering from orphan diseases and their caregivers are adopted. Official Journal, to public-legislative branch. Edition 47,758.
Colombian Congress. Mental Health Act 1616 of 2013. Which regulate the Mental Health in Colombia.
Giugliani R, et al. Mucopolysaccharidosis I, II and VI: Brief review and guidelines for treatment. Genetics and Molecular Biology 2010; 33(4): 589-604. http://dx.doi.org/10.1590/S1415-47572010005000093 DOI: https://doi.org/10.1590/S1415-47572010005000093
Bae Y, Yoon S, Won S, Jin S, Ko A, Kwon E, Ju S, Jin D. Phase I / II clinical trial of enzyme replacement therapy with idursulfase beta in patients with mucopolysaccharidosis II (Hunter Syndrome). Orphaned Journal of Rare Diseases 2013; 8(42): 1-8. DOI: https://doi.org/10.1186/1750-1172-8-42
Downloads
Published
How to Cite
Issue
Section
